tiprankstipranks
Trending News
More News >
Starpharma Holdings Limited (AU:SPL)
:SPL
Advertisement

Starpharma Holdings Limited (SPL) AI Stock Analysis

Compare
14 Followers

Top Page

AU:SPL

Starpharma Holdings Limited

(OTC:SPL)

Select Model
Select Model
Select Model
Neutral 51 (OpenAI - 4o)
Rating:51Neutral
Price Target:
AU$0.50
▲(66.67% Upside)
The overall score reflects a challenging financial performance with profitability and cash flow issues, despite strong technical indicators suggesting bullish momentum. Valuation concerns due to negative profitability further impact the score.

Starpharma Holdings Limited (SPL) vs. iShares MSCI Australia ETF (EWA)

Starpharma Holdings Limited Business Overview & Revenue Model

Company DescriptionStarpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. It offers VivaGel, a non-antibiotic therapy for the treatment and prevention of bacterial vaginosis. The company also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, it develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase 2 clinical trials, DEP cabazitaxel that is in Phase 2 clinical trial, DEP gemcitabine that is in a Phase 1/2 clinical trials, and DEP irinotecan that is in Phase 2 clinical trials for the treatment of cancer; DEP radiotheranostics for cancer treatment and diagnosis; DEP Antibody Drug Conjugates; DEP HER-2 ADC; DEP non-oncology candidates; and DEP AZD0466, which is in Phase 1/2 clinical trials to treat haematological malignancies. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
How the Company Makes MoneyStarpharma Holdings Limited generates revenue through the commercialization and licensing of its proprietary dendrimer-based technologies. The company earns money by developing and selling its VivaGel® products, which are used for various antiviral and antimicrobial applications, including sexual health and infection prevention. Additionally, Starpharma licenses its DEP® drug delivery platform to pharmaceutical companies, enabling them to improve the delivery and efficacy of their drugs. This licensing model often includes upfront payments, milestone payments, and royalties on product sales. Strategic partnerships and collaborations with major pharmaceutical companies also play a significant role in driving revenue, as they facilitate the development and commercialization of new products using Starpharma's technology.

Starpharma Holdings Limited Financial Statement Overview

Summary
Starpharma Holdings Limited shows potential with revenue growth, but consistent losses impact its financial health. The balance sheet is stable with strong cash reserves, yet negative cash flows indicate operational challenges.
Income Statement
45
Neutral
Starpharma Holdings Limited has shown significant revenue growth with a notable increase in total revenue from the previous year. However, the company continues to report negative net income and EBIT, which impacts its profitability margins. Gross profit margin is relatively high, indicating efficient cost management in production despite overall losses.
Balance Sheet
50
Neutral
The company's balance sheet reflects moderate leverage with a manageable debt-to-equity ratio. The equity ratio indicates a solid capital structure, though a decline in stockholders' equity raises concerns. Cash reserves are strong, providing a buffer against liabilities.
Cash Flow
40
Negative
Operating cash flow remains negative, highlighting cash outflows from operations. While free cash flow has improved slightly, it remains negative, which could strain liquidity. The company has managed capital expenditures well, showing discipline in investment spending.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue5.85M4.91M8.29M2.94M4.68M1.80M
Gross Profit-3.73M3.69M7.66M1.22M1.91M539.50K
EBITDA-9.72M-10.93M-9.63M-22.08M-22.34M-26.05M
Net Income-9.99M-9.99M-8.16M-15.64M-16.15M-19.73M
Balance Sheet
Total Assets25.42M25.42M36.81M52.09M66.17M73.24M
Cash, Cash Equivalents and Short-Term Investments15.41M15.41M23.36M35.18M49.92M60.50M
Total Debt2.40M2.40M3.53M8.27M8.19M1.17M
Total Liabilities6.42M6.42M8.70M17.27M17.78M10.94M
Stockholders Equity19.00M19.00M28.12M34.81M48.39M62.30M
Cash Flow
Free Cash Flow-6.80M-6.80M-7.07M-14.15M-14.00M-15.05M
Operating Cash Flow-6.76M-6.76M-6.98M-13.53M-13.16M-14.81M
Investing Cash Flow-42.00K-42.00K-89.00K-610.00K-836.00K-246.00K
Financing Cash Flow-1.13M-1.13M-4.75M-695.00K3.23M46.30M

Starpharma Holdings Limited Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.30
Price Trends
50DMA
0.16
Positive
100DMA
0.13
Positive
200DMA
0.11
Positive
Market Momentum
MACD
0.05
Negative
RSI
73.43
Negative
STOCH
78.06
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:SPL, the sentiment is Positive. The current price of 0.3 is above the 20-day moving average (MA) of 0.22, above the 50-day MA of 0.16, and above the 200-day MA of 0.11, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 73.43 is Negative, neither overbought nor oversold. The STOCH value of 78.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:SPL.

Starpharma Holdings Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
56
Neutral
AU$45.22M-49.72%10.78%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
51
Neutral
AU$127.56M-41.51%-40.74%-21.21%
47
Neutral
AU$106.59M-90.37%26.38%
46
Neutral
AU$14.28M-143.71%306.88%
43
Neutral
AU$55.80M-138.54%16.61%
36
Underperform
AU$25.72M-157.93%-36.89%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:SPL
Starpharma Holdings Limited
0.30
0.20
201.02%
AU:CYP
Cynata Therapeutics Limited
0.24
-0.02
-6.00%
AU:PTX
Prescient Therapeutics Limited
0.04
-0.01
-20.00%
AU:ILA
Island Pharmaceuticals Ltd
0.42
0.24
133.33%
AU:NOX
Noxopharm Ltd.
0.10
0.00
0.00%
AU:AVE
Avecho Biotechnology Limited

Starpharma Holdings Limited Corporate Events

Starpharma Advances DEP® Assets and Expands Global Collaborations
Jul 31, 2025

Starpharma Holdings Limited has made significant strides in maximizing the value of its DEP® assets and expanding its research collaborations. The company has been actively engaging with global stakeholders and showcasing its dendrimer technology at major conventions, while also advancing its radiotheranostics program and preparing for product launches in new markets. Despite challenges such as geopolitical complexities and a shifting oncology landscape, Starpharma remains focused on strategic execution and partnership opportunities to enhance shareholder value and improve patient outcomes.

Starpharma Announces Cessation of Performance Rights
Jul 7, 2025

Starpharma Holdings Limited announced the cessation of 716,375 performance rights due to unmet conditions, impacting its issued capital structure. This development may affect stakeholders’ perceptions of the company’s operational progress and could influence its market positioning by highlighting challenges in meeting performance targets.

Change in Substantial Holder’s Voting Power at Starpharma Holdings
Jun 3, 2025

Starpharma Holdings Limited has experienced a change in the interests of its substantial holder, UIL Limited, which has decreased its voting power from 8.02% to 6.39%. This change in voting power may impact the company’s governance dynamics and influence within the market, as substantial holders often have significant sway in decision-making processes.

Robmar Investments Alters Stake in Starpharma Holdings
Jun 3, 2025

Robmar Investments Pty Limited has filed a notice of change of interests, indicating a shift in its substantial holding in Starpharma Holdings Limited. This change could impact Starpharma’s shareholder dynamics and potentially influence its strategic decisions, reflecting broader market movements or shifts in investor confidence.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 03, 2025